Recent Updates
Recently added Catalysts
ICU Negative Sentiment Score: 20/100

SeaStar Medical Holding Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. September 6, 2024 Deadline to file Lead Plaintiff Motion.

Key Takeaway: The Portnoy Law Firm has initiated a class action lawsuit on behalf of investors in SeaStar Medical Holding Corporation who purchased shares between October 31, 2022, and March 26, 2024. Investors have until September 6, 2024, to file a lead plaintiff motion. Allegations against the company include violations of federal securities laws, false statements, and inadequate compliance controls regarding its HDE Application. Following these disclosures, SeaStar announced a restatement of its financial statements, leading to a notable decline in its stock price.

Market Sentiment Analysis

CONCERNS & RISKS

  • SeaStar Medical Holding Corporation is facing a class action lawsuit due to allegedly misleading statements.
  • The company must restate its financial statements for previous fiscal years, which raises concerns about its financial management.
  • The stock price fell by 5.41% following the announcement of the need for a restatement, indicating a loss of investor confidence.
  • The complaint also highlights inadequate compliance controls and exaggerated regulatory prospects.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU) investors of a class action representing investors that bought securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"). SeaStar investors have until September 6, 2024 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint claims that the Company and its executives broke federal securities laws by making false or misleading statements and failing to disclose the following: (i) SeaStar and/or Legacy SeaStar had inadequate compliance controls and procedures for the HDE Application; (ii) as a result, there were problems with the HDE Application, the FDA was unlikely to approve it as it was, and the SCD’s regulatory prospects were exaggerated; (iii) the Company downplayed the real extent of issues with its financial controls and procedures while overstating efforts to fix them; (iv) consequently, SeaStar failed to correctly account for certain outstanding warrants and the Prepaid Forward Agreement; (v) as a result, SeaStar might need to restate one or more of its past financial statements; (vi) therefore, SeaStar’s business and financial prospects after the Merger were exaggerated; and (vii) this made the Company’s public statements misleading at all relevant times.
On March 27, 2024, SeaStar announced it will restate its financial statements for the fiscal year ending December 31, 2022, and for interim periods ending March 31, 2023, June 30, 2023, and September 30, 2023. The Company said the restatement will affect how certain outstanding warrants and the prepaid forward purchase arrangement, terminated in June 2023, are accounted for. SeaStar's CEO explained that the restatement would not significantly affect the Company's operations or cash position, but was related to non-cash accounting items. The CEO also noted that the decision to use a Special Purpose Acquisition Company (SPAC) to go public in late 2022, due to challenging market conditions, involved complex financial instruments. It was later determined that these instruments required different accounting treatment than previously judged, leading to the need for a restatement.
Following this announcement, SeaStar’s stock price dropped by $0.04 per share, or 5.41%, closing at $0.70 per share on March 27, 2024.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff motion?

Investors have until September 6, 2024, to file a lead plaintiff motion.

Who can I contact for a free case evaluation?

You can contact attorney Lesley F. Portnoy at 310-692-8883 or email lesley@portnoylaw.com.

What will the restatement affect?

The restatement will affect the accounting of certain warrants and a prepaid forward agreement.

How much did SeaStar's stock drop after the announcement?

SeaStar's stock price fell by $0.04 per share, or 5.41%, closing at $0.70.

What type of claims does the Portnoy Law Firm handle?

The Portnoy Law Firm represents investors pursuing claims related to corporate wrongdoing.

Last updated: Aug 30, 2024